This site is intended for health professionals only

European biosimilars market anticipates rapid growth

teaser

A biosimilars market valued at $172million (E130million) in 2010 is forecast to reach $3.99billion (E30.1billion) by 2017, with a compound annual growth rate of close to 57% over the seven-year period.

 

In a recent Frost & Sullivan report, it is predicted that the growth areas will be erythropoietin, granulocyte colony-stimulating factors, human growth hormones, monoclonal antibodies, insulin and interferons. Drivers include price reduction concurrent with escalating doctor and patient uptake. But while this will offer lucrative opportunities for large companies, the level of investment for smaller firms – in materials as well as in clinical trials proving safety, efficacy and quality – is likely to prove a serious challenge. 

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
Advertisement

 

Companies ‘need to have strongly-integrated R&D, production, sales and marketing processes to ensure market success ‘ and ‘effective sales communication to the scientific community, coupled with continuous promotional activities as well as close and constant interaction with doctors and pharmacists’ so as to ensure greater and faster uptake of biosimilars, the report concludes.

 

Frost & Sullivan






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

×